Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| The Gerber Foundation | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess whether the type of anesthesia, narcotic-based versus inhalational anesthesia administered during cardiopulmonary bypass (CPB) surgery contributes to the wide variation in neurologic recovery and developmental outcome after surgery in infants with congenital heart disease.
All subjects will be consented prior to participation in this study and prior to randomization.
All the subjects enrolled in the study will receive a preoperative assessment by one of the cardiac anesthesiologists and receive standardized induction with sevoflurane up to 2%, 2 mcg/kg of fentanyl and 1 mg/kg of rocuronium. The anesthetic maintenance will be determined using a computer- generated randomization table and assigning each patient to one of the two anesthetic regimens. Both of these anesthetic techniques are standard of care and are commonly used for these procedures.
Anesthetic Technique:
Volatile anesthetic:
In volatile anesthetic technique, maintenance of anesthesia will be standardized to the volatile anesthetic isoflurane. Isoflurane will be used for the study since this is what is presently available on the CPB machines. Anesthesia at 1.0 minimum anesthetic concentration (MAC) indicates that at this concentration 50% of the patients will not move when surgically stimulated. Anesthesiologists commonly use about 1.2-1.4 MAC in neonates, since the MAC value in infants is higher than that of children and adults. Isoflurane will be delivered at 1.5-2.0%% as required for anesthetic management.
Rocuronium or pancuronium will be used for muscle relaxation. Narcotic, fentanyl will be administered at no greater than 2 mcg/kg/hr.
Narcotic-based anesthetic:
In narcotic based anesthetic technique, no volatile anesthetics will be used except during induction.
Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr.
The anesthetic may be supplemented with dexmedetomidine 0.05 mcg/kg/hr but not to exceed 1.0 mcg/kg/hr. Narcotic-based anesthetic will be used by the cardiac anesthesia team and the CPB technician throughout the operative case. 5 mcg/kg/hr of fentanyl is felt to represent 0.6 MAC of anesthesia.
Postoperative Sedative and Analgesic Care:
As per institutional standard of care, postoperative sedation will consist of fentanyl infusions of 2-4 mcg/kg/hr for the first 48 hours postoperatively.
A total of 9 Blood samples will be collected at different time points throughout the entire study for metabolomics determination (NAA/Cr and Chol/Cr)
EEG monitoring will be done for baseline in the pre-operative period for 15-20 minutes, during surgery and post-operatively up to 48 hours and prior to discharge for 15-20 minutes. Neurological and behavioral testing including Bayley Exam III will be done at 18-48 months.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Volatile Anesthesia | Active Comparator | In volatile anesthetic technique, maintenance of anesthesia will be standardized to the anesthesia will be standardized to the volatile anesthetic isoflurane. Rocuronium or pancuronium will be used for muscle relaxation. Additionally, narcotic fentanyl will be administered at no greater than 2 mcg/kg/hr (low dose). However, the primary anesthetic during CPB will be isoflurane with no narcotic administered during CPB. |
|
| Narcotic based anesthesia | Active Comparator | In narcotic based anesthetic technique, no volatile anesthetics will be used past induction. Maintenance of anesthesia will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Isoflurane | Drug | Isoflurane (volatile anesthesia) will be delivered at 1.5-2.0%% as required for anesthetic management. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Bayley III | Neurodevelopmental assessment scores are age dependent and based motor and behavioral abilities, often reported for normal or abnormal for age. Bayley Scales of Infant and Toddler Development, third edition, (Bayley III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items, score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit. | Assessed once between age 18 to 48 months (approximately 2 hours to assess), up to 48 months from study start |
| Electroencephalogram | Brain electrical activity: observation is for brain region specific abnormal or seizure activity. Number of participants with abnormal EEG are reported. | EEG taken immediately prior to surgery, during surgery, during cardiovascular intensive care unit (CVICU) stay (up to 48 hours after surgery), and immediately prior to discharge (between 5 to 20 minutes to assess EEG at each time point) |
| Measure | Description | Time Frame |
|---|---|---|
| Choline | blood levels: time and patient dependent variation, observed patient related trends over time | 0-72 hours |
| Glutamate | blood levels:time and patient dependent variation, observed patient related trends over time |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Lisa W Faberowski, MD, MSc | Stanford University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford Childrens hospital | Palo Alto | California | 94305 | United States |
No IPD will be shared with other researchers
Not provided
Not provided
Not provided
Not provided
Randomization data are available for only 89 of the 153 participants enrolled.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Narcotic Based Anesthesia | Participants receive fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose). |
| FG001 | Volatile Anesthesia | Participants receive volatile anesthetic isoflurane (1.5-2.0%) as primary anesthetic; participants also receive rocuronium or pancuronium for muscle relaxation, and fentanyl at no greater than 2 mcg/kg/hr (low dose). |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Participants with randomization data are included in the analysis.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Narcotic Based Anesthesia | Participants receive fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose). |
| BG001 | Volatile Anesthesia | Participants receive volatile anesthetic isoflurane (1.5-2.0%) as primary anesthetic; participants also receive rocuronium or pancuronium for muscle relaxation, and fentanyl at no greater than 2 mcg/kg/hr (low dose). |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Bayley III | Neurodevelopmental assessment scores are age dependent and based motor and behavioral abilities, often reported for normal or abnormal for age. Bayley Scales of Infant and Toddler Development, third edition, (Bayley III) is an instrument designed to measure the developmental functioning of infants and toddlers between the ages of 1 month and 42 months (age adjustments for prematurity are accommodated with the tool). It provides age specific composite scores for cognitive (91 items, score min 55 max 145), language (98 items, score min 47 max 153), and motor (138 items, score min 46 max 154) skills. For all scales, higher scores are better and lower scores indicate possible delay/deficit. | Participants with a completed Bayley III assessment are included in the analysis. | Posted | Mean | Standard Deviation | score on a scale | Assessed once between age 18 to 48 months (approximately 2 hours to assess), up to 48 months from study start |
|
48 months
Participants with randomization data are included in the analysis.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Narcotic Based Anesthesia | Participants receive fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose). |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Cardiopulmonary arrest | Cardiac disorders | Systematic Assessment |
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Clinical Trials Manager | Research Office | 650-724-1720 | clinicaltrials-gov@stanford.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 14, 2012 | Feb 10, 2022 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D006330 | Heart Defects, Congenital |
| D065886 | Neurodevelopmental Disorders |
| ID | Term |
|---|---|
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D007530 | Isoflurane |
| D005283 | Fentanyl |
| ID | Term |
|---|---|
| D008738 | Methyl Ethers |
| D004987 | Ethers |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
Not provided
Not provided
Not provided
Not provided
Not provided
EEG, metabolic/NMRS analysis and neurodevelopment outcome is blinded.
| Fentanyl (high dose) | Drug | Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr. |
|
| Fentanyl (low dose) | Drug | Fentanyl (narcotic anesthesia) maintenance will be with fentanyl 2 mcg/kg/hr. |
|
| 0-72 hours |
| N-acetylaspartate (Naa) | blood levels:time and patient dependent variation, observed patient related trends over time | 0-72 hours |
| Lactate | blood levels:time and patient dependent variation, observed patient related trends over time | 0-72 hours |
| BG002 | Total | Total of all reporting groups |
| months |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
Participants receive fentanyl 5 mcg/kg/hr not to exceed 10 mcg/kg/hr (high dose). |
| OG001 | Volatile Anesthesia | Participants receive volatile anesthetic isoflurane (1.5-2.0%) as primary anesthetic; participants also receive rocuronium or pancuronium for muscle relaxation, and fentanyl at no greater than 2 mcg/kg/hr (low dose). |
|
|
| Primary | Electroencephalogram | Brain electrical activity: observation is for brain region specific abnormal or seizure activity. Number of participants with abnormal EEG are reported. | Posted | Count of Participants | Participants | No | EEG taken immediately prior to surgery, during surgery, during cardiovascular intensive care unit (CVICU) stay (up to 48 hours after surgery), and immediately prior to discharge (between 5 to 20 minutes to assess EEG at each time point) |
|
|
|
| Secondary | Choline | blood levels: time and patient dependent variation, observed patient related trends over time | Data were not collected for this outcome measure. | Posted | 0-72 hours |
|
|
| Secondary | Glutamate | blood levels:time and patient dependent variation, observed patient related trends over time | Data were not collected for this outcome measure. | Posted | 0-72 hours |
|
|
| Secondary | N-acetylaspartate (Naa) | blood levels:time and patient dependent variation, observed patient related trends over time | Data were not collected for this outcome measure. | Posted | 0-72 hours |
|
|
| Secondary | Lactate | blood levels:time and patient dependent variation, observed patient related trends over time | Data were not collected for this outcome measure. | Posted | 0-72 hours |
|
|
| 3 |
| 44 |
| 7 |
| 44 |
| 0 |
| 44 |
| EG001 | Volatile Anesthesia | Participants receive volatile anesthetic isoflurane (1.5-2.0%) as primary anesthetic; participants also receive rocuronium or pancuronium for muscle relaxation, and fentanyl at no greater than 2 mcg/kg/hr (low dose). | 1 | 45 | 10 | 45 | 0 | 45 |
| Hypotension | Cardiac disorders | Systematic Assessment |
|
| Arrythmia | Cardiac disorders | Systematic Assessment |
|
| Bleeding | Vascular disorders | Systematic Assessment |
|
| Sepsis | Blood and lymphatic system disorders | Systematic Assessment |
|
| Metabolic acidosis | Metabolism and nutrition disorders | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D001523 | Mental Disorders |
| D006573 |
| Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| Abnormal EEG in CVICU |
|
| Abnormal EEG predischarge |
|